Cancer cure for 32 cancer types: results from the EUROCARE-5 study

Maso, Luigino Dal; Panato, Chiara; Tavilla, Andrea; Guzzinati, Stefano; Serraino, Diego; Mallone, Sandra; Botta, Laura; Boussari, Olayidé; Capocaccia, Riccardo; Colonna, Marc; Crocetti, Emanuele; Dumas, Agnès; Dyba, Tadeusz; Franceschi, Silvia; Gatta, Gemma; Gigli, Anna; Giusti, Francesco; Jooste, Valérie; Minicozzi, Pamela; Neamţiu, Luciana; Romain, Gaëlle; Zorzi, Manuel; Angelis, Roberta De; Francisci, Silvia

doi:10.1093/ije/dyaa128

Cited by 55 publications

(58 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One can assume that patients surviving 5 years may have a good chance of being cured, and this varied for 60 to 70% for all but hypopharyngeal cancer for which male survival was barely 25%. Time to cure is dependent on diagnostic age and for cancer of the oral cancity and pharynx it varies from about 7 years at age 15–44 years to about 17 at age 65–74 [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

Incidence and survival in oral and pharyngeal cancers in Finland and Sweden through half century

et al. 2022

View full text Add to dashboard Cite

Background Cancers of the oral cavity and pharynx encompass a heterogeneous group of cancers for which known risk factors include smoking, alcohol consumption and human papilloma virus (HPV) infection but their influence is site-specific with HPV mainly influencing oropharyngeal cancer. Their incidence and survival rates are not well known over extended periods of time. Patients/methods Data were obtained for Finnish (FI) and Swedish (SE) patients from the Nordcan database recently updated through 2019. Age-adjusted incidence trends (FI from 1953, SE from 1960) and relative survival rates for years 1970 through 2019 were calculated. Results We observed a prominent increase in oral and oropharyngeal cancers in FI and SE men and women but the trend for oral cancer was interrupted for SE men in 1985 and possibly also for FI and SE women in 2015. The trend changes in male and female oral cancer was confirmed in data for Denmark and Norway. Relative survival for these cancers has improved overall but they differed for one cluster of oral, oropharyngeal and nasopharyngeal cancers with 60–70% 5-year survival in the last period and hypopharyngeal cancer with 25% male survival. In all these cancers, survival for old patients was unfavorable. Discussion/conclusion We hypothesize that reduction in smoking prevalence helped to stop the increase in oral cancer especially in men. As the prevalence of smoking is decreasing, HPV is becoming a dominant risk factor, particularly for the increasing oropharyngeal cancer. Prevention needs to emphasize sexual hygiene and HPV vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence and survival in oral and pharyngeal cancers in Finland and Sweden through half century

et al. 2022

View full text Add to dashboard Cite

show abstract

“…37 The prognosis of liver cancer from population-based registered cases is actually an embodiment of this capacity of comprehensive treatment and health service, so it is different from the results of a certain therapy or the treatment capacity of a certain hospital. The EUROCARE studies or CONCORD series research have provided the world a large number of results from population-based registration, 11,12 but each of these studies basically reflected the sectional results of certain periods by country or region, and may not deduce the historical changes (trends). In this study, based on the long-run collection of all liver cancer cases from all residents in a coverage area of a population-based cancer registry in China, the characteristics and changes of liver cancer survival rates in a 45-year period is analyzed, providing an example of realworld profile for the estimation of long-term trends of liver cancer survival.…”

Section: Discussionmentioning

confidence: 99%

“…These research reports have provided very useful information on the general efficiency of cancer health services, based on data from many countries or areas, reflecting a period results for a region, a continent, or five continents. [11][12][13][14] Recent years, within the oncology community, growing interest exists in using data from the real world to address clinical and policy-relevant questions, hence resulting in increased reporting of studies using real world data (RWD). 15 However, there are few reports derived from long-run population-based cancer registration systems for over decades.…”

Section: Introductionmentioning

confidence: 99%

Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases

Chen¹,

Zhu²,

Zhang³

et al. 2021

JHC

View full text Add to dashboard Cite

Background and Aims: To explore the long-term trend of liver cancer survival, based on the real-world data (RWD) in the past 45 years from a population-based cancer registry, in Qidong, China. Methods: A number of 32,556 patients with liver cancer were registered during the period of 1972 to 2016. Mixed methods by active and passive follow-up were performed. Life table method was employed for survival analysis by SPSS22 software. Wilcoxon (Gehan) statistics was considered as a significant test. Relative survival was calculated by using SURV software, and its annual percent change (APC) was estimated by the Joinpoint Regression Program. Results: The overall observed survival (OS) rates of 1-, 5-, 10-, and 20-year rates from the data series were 18.51%, 6.28%, 4.03%, and 2.84%, and their relative survival (RS) rates were 18.88%, 6.95%, 4.96%, and 4.49%, respectively. For 24,338 male cases, the 5-year OS and RS rates were 5.93% and 6.54%, and for 8218 female cases, 7.34% and 8.15%, respectively, with P values less than 0.01. Survival rates of liver cancer from three 15-year periods of 1972-1986, 1987-2001, and 2002-2016 have increased significantly, with 5-year OS rates of 2.02%, 4.40%, and 10.76%, 5-year RS rates of 2.18%, 4.83%, and 12.18%; 10year OS and RS rates of 0.95%, 3.00%, and 7.02%, vs 1.13%, 3.65%, and 8.96%, respectively, showing a very significant upward trend (P<0.01). There are significant differences among age groups (P<0.01): those aged 55-64 demonstrated the best OS and RS rates of 5-year, being 8.44% and 9.09%, respectively. Conclusion: There are significant gender and age differences in the survival rate of liver cancer in Qidong. RWD indicates the relative lower survival rate of liver cancer in this area, but great improvement has been achieved over the past decades.

show abstract

“…Importantly in the last years, the number of individuals living after a cancer diagnosis (i.e., cancer prevalence) is growing by approximately 3% annually [ 78 , 79 ]. Cancer survivors currently represent more than 5% of the overall population in several countries [ 80 ]. As reported by the EUROCARE‐6 study and the iPAAC Joint Action, more than 20 million people live after a cancer diagnosis in Europe, marking an increase of + 45% in the period from 2010 to 2020 (13.8–20 million) [ 81 ].…”

Section: Infrastructure For Outcomes Researchmentioning

confidence: 99%

The Porto European Cancer Research Summit 2021

et al. 2021

View full text Add to dashboard Cite

Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high‐quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research across the entire cancer continuum to support the development of personalized/precision cancer medicine in Europe. The three pillars of the recommended European infrastructures – namely translational research, clinical/prevention trials and outcomes research – were pondered at length. Speakers addressing the future needs of translational research focused on the prospects of multiomics assisted preclinical research, progress in Molecular and Digital Pathology, immunotherapy, liquid biopsy and science data. The clinical/prevention trial session presented the requirements for next‐generation, multicentric trials entailing unified strategies for patient stratification, imaging, and biospecimen acquisition and storage. The third session highlighted the need for establishing outcomes research infrastructures to cover primary prevention, early detection, clinical effectiveness of innovations, health‐related quality‐of‐life assessment, survivorship research and health economics. An important outcome of the Summit was the presentation of the Porto Declaration, which called for a collective and committed action throughout Europe to develop the cancer research infrastructures indispensable for fostering innovation and decreasing inequalities within and between member states. Moreover, the Summit guidelines will assist decision making in the context of a unique EU‐wide cancer initiative that, if expertly implemented, will decrease the cancer death toll and improve the quality of life of those confronted with cancer, and this is carried out at an affordable cost.

show abstract

Cancer cure for 32 cancer types: results from the EUROCARE-5 study

Cited by 55 publications

References 43 publications

Incidence and survival in oral and pharyngeal cancers in Finland and Sweden through half century

Incidence and survival in oral and pharyngeal cancers in Finland and Sweden through half century

Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases

The Porto European Cancer Research Summit 2021

Contact Info

Product

Resources

About